$36.41
0.130.36%
Last update: Nov 2, 6:25 PM
Indivior Pharmaceuticals Inc Ordinary Share
INDVNASDAQ
Indivior Pharmaceuticals Inc Ordinary Share rose 20.5% from $30.10 to $36.28, ahead of the S&P 500's +11.2%. Its worst day was Aug 3 (−6.6%), and its low came Mar 30 at $28.78.
Nov 12, 2025 – Nov 2, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $0.82 beat the $0.66 estimate on $358.0M revenue (est. $305.5M); FY revenue guidance of $1.1B–$1.2B against the $1.1B consensus.
+0.2% · S&P 500 −0.6%
Story events cover the past 12 months · Times ET
Indivior Pharmaceuticals Inc Ordinary Share shares fell 6.0%, while the S&P 500 fell 1.5%.
−6.0% · S&P 500 −1.5%
Indivior Pharmaceuticals Inc Ordinary Share closed at its lowest level of the year, 4.4% below where the year started.
−0.7% · S&P 500 −0.3%
Indivior Pharmaceuticals Inc Ordinary Share shares fell 5.5%, while the S&P 500 fell 0.1%.
−5.5% · S&P 500 −0.1%
EPS of $0.96 beat the $0.66 estimate on $317.0M revenue (est. $272.0M); FY revenue guidance of $1.2B–$1.3B against the $1.2B consensus.
+7.7%, the year's best day · S&P 500 +1.0%
Indivior Pharmaceuticals Inc Ordinary Share shares rose 5.7%, while the S&P 500 rose 0.4%.
+5.7% · S&P 500 +0.4%
Indivior Pharmaceuticals Inc Ordinary Share closed at its highest level of the year, 39.0% above where the year started.
+1.3% · S&P 500 −0.7%
EPS of $1.15 beat the $0.92 estimate on $343.0M revenue (est. $306.8M); FY revenue guidance of $1.3B–$1.4B against the $1.3B consensus.
−6.6%, the year's worst day · S&P 500 +1.4%
EPS of $1.32 beat the $1.08 estimate on $356.0M revenue (est. $328.8M); FY revenue guidance of $1.3B–$1.4B against the $1.3B consensus.
+1.4% · S&P 500 −0.4%
Where it ended: a close of $36.28 on Nov 2, 2026. Up next: Q4 2026 earnings on Feb 25, 2027 (EPS est. $1.19, revenue est. $336.6M).
Nothing in the past 12 months.
All INDV dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for INDV and SPY from Benzinga historical bars. Not investment advice.
